Rallybio gains on promising pre-clinical data from bleeding disorder treatment study

Rallybio

15/12/2022 19:07

** Rare diseases therapies developer Rallybio Corp's
 RLYB.O  shares rise 10.2% at $7
    ** Company reports positive pre-clinical study results for
two antibodies in development for prevention of a rare,
life-threatening bleeding disorder, FNAIT, in pregnant women
    ** Including session's gain, stock down ~27% YTD
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))